Inceptor Bio

Inceptor Bio

  • Founded: 2020
  • Location: Raleigh, NC
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $37M A May 2022

job board

Short description:

Cell & Gene Therapy Manufacturing Platform

Drug notes:

2 additional undisclosed programs RD/Clin0 oncology

Long description:

Inceptor Bio is developing next-generation cell and gene therapy platforms to deliver cures for underserved and difficult-to-treat cancers. The company has a proprietary CAR-M platform, which uses monocytes and macrophages engineered with a Chimeric Antigen Receptor (CAR) to identify and attack cancer cells. Inceptor Bio's CAR-M platform has several advantages over other cell therapy approaches, including: increased infiltration into tumors, enhanced phagocytosis, overcoming the CD47/SIRP⍺ ('Don't Eat Me') signal. Inceptor Bio is currently developing CAR-M therapies for a variety of solid tumors, including pancreatic cancer, glioblastoma, and non-small cell lung cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy